This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The health care community is actively debating the ethics of placebo-controlled trials in diseases with uniform or high mortality. This debate, which has been particularly active for AIDS and breast cancer, now involves ALS trials. Patients are increasingly reluctant to enter randomized placebo-controlled trials (RPCTs), particularly when the drug being tested is safe and available through other sources. The ramifications of what appears to be a significant shift in societal attitudes is more than an academic debate and poses a serious threat to successful evaluation of promising therapeutic agents. We believe that a careful reassessment of current clinical trial design in ALS is necessary, and it is appropriate to explore the role of alternatives to randomized placebo control subjects, alternatives that could meet both scientific and humanitarian needs. In this report, we extend our studies on the natural history of ALS and suggest ways in which a natural history database can be used in phase II trials.
Use of natural history control subjects in the design of therapeutic trials.
Over the years, an inordinate number of drugs have been reported to be effective in ALS, only to …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.